CN101735196A - Method for synthesizing Imatinib - Google Patents
Method for synthesizing Imatinib Download PDFInfo
- Publication number
- CN101735196A CN101735196A CN200810202634A CN200810202634A CN101735196A CN 101735196 A CN101735196 A CN 101735196A CN 200810202634 A CN200810202634 A CN 200810202634A CN 200810202634 A CN200810202634 A CN 200810202634A CN 101735196 A CN101735196 A CN 101735196A
- Authority
- CN
- China
- Prior art keywords
- methyl
- formula
- imatinib
- synthetic method
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses a method for synthesizing Imatinib, comprising the following steps: under the action of alkali, 4-methyl-N-3-(4-pyridine-3-radix-pyrimidine-2-radix)-1,3-phenylenediamine shown in the formula (I) reacts with 4-(4-methylpiperazine-1-methyl)-benzoate shown in the formula (II) in an aprotic inorganic solvent to form the Imatinib shown in the formula (III), namely 4-(4-methylpiperazine-1-methyl)-N-[4-methyl-3-[4-(3-pyridyl) pyrimidine-2-amino]-benzamide. In the above chemical structure general formula, R represents fatty alkyl, phenyl, substituted phenyl, benzyl or substituted benzyl containing 1-10 carbon atoms. The invention provides the new method for synthesizing Imatinib, which has mild reaction conditions and high yield and is environment-friendly.
Description
Technical field
The invention belongs to the organic synthesis field, particularly a kind of synthesizing imatinib.
Background technology
Imatinib mesylate is that a signal transduction inhibitor (being former STI571) is successfully studied in effort that Novartis Co.,Ltd was passed through 7 years, is first tumour generation coherent signal conduction depressant drug that gets the Green Light of the whole world.Imatinib mesylate obtains lonely rare medicine status in states such as the U.S., European Union and Japan, and in the approval of acquisition FDA Food and Drug Administration on May 10 calendar year 2001 (FDA), the chronic lymphocytic leukemia patient who be used for the treatment of alpha-interferon (interfer on-alfa) treatment failure protoblast crisis stadium, quickens stadium or chronic stadium.
The chemistry of imatinib (Imatinib) is by name: 4-(4-methylpiperazine base-1-methyl)-N-[4-methyl-3-[4-(3-pyridyl) pyrimidine-2-amino]-benzamide, structural formula is as follows:
The synthetic route of imatinib is suitable for industrializedly reducing two.Route one is a starting raw material with 2-methyl-5-nitro aniline, generate guanidine with the cyanamide reaction earlier, carry out ring-closure reaction with 3-dimethylamino-1-(3-pyridyl)-2-propylene-1-ketone then, again nitroreduction is become amino, then carry out condensation reaction successively with to chloromethyl benzoic acid chlorides and N methyl piperazine, make imatinib (WO 2004/108699).
Route two is a starting raw material with 4-methyl-3-nitro aniline, earlier carry out condensation reaction successively with to chloromethyl benzoic acid chlorides and N methyl piperazine, then nitroreduction is become amino, generate guanidine with the cyanamide reaction again, then carry out ring-closure reaction, make imatinib (WO 03/066613) with 3-dimethylamino-1-(3-pyridyl)-2-propylene-1-ketone.
The response hierarchy difference that is the cyclization pyrimidine ring of the difference maximum of two lines.But all there is following shortcoming in these two lines: 1) because the use cyanamide synthesizes guanidine radicals, and cyanamide is lower boiling, highly volatile, thereby the yield of guanidine radicals is low and unstable; 2) synthesis yield of pyrimidine ring is low, long reaction time, and raw material reaction is incomplete.
Chinese patent CN1630648A also discloses a kind of synthesizing imatinib.This method uses 3-bromo-4-monomethylaniline to be raw material, aminolysis reaction with trimethyl aluminium realization and 4-(4-methyl-piperazinyl-methyl) methyl benzoate obtains N-(4-methyl-3-bromophenyl)-4-(4-methyl-piperazinyl-1-methyl)-benzamide, obtains imatinib with precious metal palladium catalysis and PYRIMITHAMINE reaction at last.Its maximum shortcoming is 1) trimethyl aluminium that uses is that ignition control compound and water contact reacts are violent; 2) final product has 10% isomer, is difficult to purifying.
Chinese patent CN101016293A discloses another kind of synthesizing imatinib.This method is that raw material and 2-halo-4-methyl-(3-pyridyl)-pyrimidine reaction obtain imatinib with N-(4-methyl-3-3 aminophenyl)-4-(4-methyl-piperazinyl-1-methyl)-benzamide also.Halogenating agent such as phosphorus oxychloride that this method is used when Synthetic 2-halo-4-methyl-(3-pyridyl)-pyrimidine belong to highly toxic product, and be very big to the influence of environment.
Summary of the invention
Therefore, the technical problem to be solved in the present invention is exactly the defective that exists in the existing synthesizing imatinib, and a kind of new synthesizing imatinib is provided, and this synthesising method reacting condition gentleness is environmentally friendly, the yield height.
The present invention solves the problems of the technologies described above the technical scheme that is adopted: a kind of synthesizing imatinib, it is characterized in that, may further comprise the steps: in organic solvent, under the effect of alkali, formula, (I) the 4-methyl-N-3-shown in, (4-pyridin-3-yl-pyrimidine-2-base)-1,3-phenylenediamine and formula, (II) 4-shown in, (4-methylpiperazine-1-methyl)-benzoic ether reacts, form formula, (III) imatinib shown in, be 4-, (4-methylpiperazine-1-methyl)-N-[4-methyl-3-[4-, (3-pyridyl) pyrimidine-2-amino]-benzamide
In the above-mentioned chemical structure of general formula, R represents the fatty alkyl of 1～10 carbon, phenyl, substituted-phenyl, benzyl or substituted benzyl.
Among the present invention, the fatty alkyl of a described 1-10 carbon is methyl, ethyl or propyl group preferably, and described substituted-phenyl is p-methylphenyl preferably, and described substituted benzyl is preferably to methoxy-benzyl.
Among the present invention, described alkali can be selected from organic bases and mineral alkali.Described organic bases preferably is selected from one or more in sodium alkoxide, potassium alcoholate, butyllithium, isobutyl-lithium, tert-butyl lithium, sodium hydroxide, potassium hydroxide, lithium hydroxide, cesium hydroxide and the salt of wormwood.Wherein, described sodium alkoxide preferably is selected from sodium methylate, sodium ethylate, sodium propylate, sodium butylate, sodium tert-butoxide and benzylalcohol sodium, and described potassium alcoholate preferably is selected from potassium methylate, potassium ethylate, potassium propylate, butanols potassium, potassium tert.-butoxide and potassium benzyl alcoholate.That the concentration of described alkali is preferable is 0.1～10M, and that better is 1～2M.
Among the present invention, described organic solvent is preferable is selected from tetrahydrofuran (THF), ether, methylene dichloride, 1, one or more in alcohol, toluene, ethyl acetate, dimethyl formamide, methyl-sulphoxide and the dimethylbenzene of 2-ethylene dichloride, acetonitrile, 1～4 carbon.
Among the present invention, what the reaction mol ratio of the compound shown in compound shown in the formula (I) and the formula (II) was preferable is 1: 1～1: 10, and best is 1: 1.5～1: 4.The consumption of organic solvent is the conventional amount used in the organic synthesis.
Among the present invention, what the temperature of reaction of described reaction was preferable is 0～100 ℃, and better is 25～50 ℃.The reaction times of described reaction preferable for till detecting reaction raw materials and no longer reducing.
The synthetic method of the compound shown in the formula (I) can be referring to patent WO 2004/108699:
2-methyl-5-nitro aniline and cyanamide reaction obtain 2-methyl-5-nitro guanidines, and itself and 3-dimethylin-1-pyridin-3-yl acetone reaction obtain the pyrimidine ring compound, and the nitro that reduces then obtains the compound shown in the formula (I).
The synthetic method of the compound shown in the formula (II) can be referring to document syn.comm.2003,3597, comprise the steps: to cyano group halogen benzyl or to the sulphonate of cyano-benzyl alcohol and methylpiperazine reaction, hydrolysis cyano group is acid then, last and corresponding alcohol reaction obtains corresponding ester, i.e. compound shown in the formula (II);
In the said structure, R represents the fatty alkyl of 1～10 carbon, phenyl, substituted-phenyl, benzyl or substituted benzyl; X represents Cl, Br, I, OMS or OTS.
Raw material that the present invention is used or reagent except that specifying, all commercially available getting.
Than prior art, beneficial effect of the present invention is as follows:
1, in the inventive method, the aminolysis reaction of ester is totally complete, and yield improves greatly,
2, in the inventive method, the by product of aminolysis reaction is corresponding alcohol, and is environmentally friendly,
3, in the inventive method, the reaction conditions gentleness, easy handling is beneficial to suitability for industrialized production.
Embodiment
Further specify the present invention with embodiment below, but the present invention is not limited.The experimental technique of unreceipted actual conditions in the following example, usually according to normal condition, or the condition of advising according to manufacturer.
Embodiment 1 imatinib,
In the 500ml exsiccant four-hole bottle, add tetrahydrofuran (THF) 250ml, 4-methyl-N-3-(4-pyridin-3-yl-pyrimidine-2-base)-1,3-phenylenediamine 27.7g and 4-(4-methylpiperazine-1-methyl)-methyl benzoate 25g is after the stirring and dissolving, add sodium methylate 10g, heat 70 ℃ of back flow reaction and spend the night, concentrate tetrahydrofuran (THF) after detection reaction is complete, the solid washing that obtains, dry imatinib 45g, the yield 91.0% of getting.
Spectroscopic data is as follows:
1H?NMR(500M，DMSO)δ：10.2(s，1H)，9.30(s，1H)，8.99(s，1H)，8.72(d，J＝4.0Hz，1H)，8.57(s，1H)，8.53(s，1H)，8.11(s，1H)，8.00(s，1H)，7.98(s，1H)，7.58-7.51(m，4H)，7.44(d，J＝4.3Hz，1H)，7.22(d，J＝8.1Hz，1H)，3.70(s，2H)，3.50-3.25(m，2H)，3.20-2.90(m，4H)，2.81(s，3H)，2.40(s，3H)，2.24(s，3H).
13C?NMR(125M，DMSO)δ：164.9，161.3，161.1，159.4，150.8，147.7，137.7，137.1，134.9，134.3，132.3，129.9，129.1，127.7，127.6，123.9，117.2，116.8，107.5，59.9，52.1，48.9，42.2，17.5.
MS(M
++1)：494.3
Embodiment 2
In the 5000ml exsiccant four-hole bottle, add methylene dichloride 3000ml, 4-methyl-N-3-(4-pyridin-3-yl-pyrimidine-2-base)-1,3-phenylenediamine 277g and 4-(4-methylpiperazine-1-methyl)-ethyl benzoate 270g is after the stirring and dissolving, add sodium methylate 100g, heat 40 ℃ of back flow reaction and spend the night, concentrate toluene after detection reaction is complete, the solid washing that obtains, dry imatinib 455g, the yield 92.0% of getting.Spectroscopic data is the same.
Embodiment 3
In the 5000ml exsiccant four-hole bottle, add toluene 3000ml, 4-methyl-N-3-(4-pyridin-3-yl-pyrimidine-2-base)-1,3-phenylenediamine 277g and 4-(4-methylpiperazine-1-methyl)-peruscabin 450g is after the stirring and dissolving, add sodium ethylate 200g, be heated to 50 ℃ of reactions and spend the night, concentrate toluene after detection reaction is complete, the solid washing that obtains, dry imatinib 445g, the yield 90.0% of getting.Spectroscopic data is the same.
Embodiment 4
Add 25 liters of dimethyl formamides in 50 liters of reactors, 4-methyl-N-3-(4-pyridin-3-yl-pyrimidine-2-base)-1,3-phenylenediamine 2.77kg and 4-(4-methylpiperazine-1-methyl)-propyl benzoate 3.50kg is after the stirring and dissolving, add butanols potassium 3kg, be heated to 50 ℃ of reactions and spend the night, detection reaction is separated out solid in falling back fully, centrifugal, the solid washing that obtains, dry imatinib 4.45kg, the yield 90.0% of getting.Spectroscopic data is the same.
Embodiment 5
In the 5000ml exsiccant four-hole bottle, add acetonitrile 3000ml, 4-methyl-N-3-(4-pyridin-3-yl-pyrimidine-2-base)-1,3-phenylenediamine 277g and 4-(4-methylpiperazine-1-methyl)-phenylformic acid is to methoxy benzyl ester 450g, after the stirring and dissolving, add butyllithium 400ml (2.5M), be heated to 20 ℃ of reactions and spend the night, concentrate acetonitrile after detection reaction is complete, the solid washing that obtains, dry imatinib 445g, the yield 90.0% of getting.Spectroscopic data is the same.
Embodiment 6
In the 5000ml exsiccant four-hole bottle, add propyl alcohol 3000ml, 4-methyl-N-3-(4-pyridin-3-yl-pyrimidine-2-base)-1,3-phenylenediamine 277g and 4-(4-methylpiperazine-1-methyl)-phenylformic acid phenyl ester 2250g is after the stirring and dissolving, add cesium hydroxide 1500g, be heated to 80 ℃ of reactions and spend the night, concentrate propyl alcohol after detection reaction is complete, the solid washing that obtains, dry imatinib 450g, the yield 90.5% of getting.Spectroscopic data is the same.
Embodiment 7
In the 5000ml exsiccant four-hole bottle, add ethyl acetate 3000ml, 4-methyl-N-3-(4-pyridin-3-yl-pyrimidine-2-base)-1,3-phenylenediamine 277g and 4-(4-methylpiperazine-1-methyl)-phenylformic acid p-methylphenyl ester 450g is after the stirring and dissolving, add salt of wormwood 138g, be heated to 50 ℃ of reactions and spend the night, concentrate ethyl acetate after detection reaction is complete, the solid washing that obtains, dry imatinib 445g, the yield 90.0% of getting.Spectroscopic data is the same.
Embodiment 8
In the 5000ml exsiccant four-hole bottle, add methyl-sulphoxide 3000ml, 4-methyl-N-3-(4-pyridin-3-yl-pyrimidine-2-base)-1,3-phenylenediamine 277g and 4-(4-methylpiperazine-1-methyl)-phenylformic acid p-methylphenyl ester 450g is after the stirring and dissolving, add sodium hydroxide 800g, be heated to 70 ℃ of reactions and spend the night, concentrate methyl-sulphoxide after detection reaction is complete, the solid washing that obtains, dry imatinib 445g, the yield 90.0% of getting.Spectroscopic data is the same.
Embodiment 9
In the 5000ml exsiccant four-hole bottle, add ether 3000ml, 4-methyl-N-3-(4-pyridin-3-yl-pyrimidine-2-base)-1,3-phenylenediamine 277g and 4-(4-methylpiperazine-1-methyl)-peruscabin 1500g is after the stirring and dissolving, add benzylalcohol sodium 1000g (1mol), 0 ℃ of reaction is spent the night, and concentrates ether after detection reaction is complete, the solid washing that obtains, dry imatinib 445g, the yield 90.0% of getting.Spectroscopic data is the same.
Claims (8)
1. synthesizing imatinib, it is characterized in that, may further comprise the steps: in organic solvent, under the effect of alkali, 4-methyl-N-3-shown in the formula (I) (4-pyridin-3-yl-pyrimidine-2-base)-1, the 4-shown in 3-phenylenediamine and the formula (II) (4-methylpiperazine-1-methyl)-benzoic ether reacts, and forms the imatinib shown in the formula (III), be 4-(4-methylpiperazine-1-methyl)-N-[4-methyl-3-[4-(3-pyridyl) pyrimidine-2-amino]-benzamide
In the above-mentioned chemical structure of general formula, R represents the fatty alkyl of 1～10 carbon, phenyl, substituted-phenyl, benzyl or substituted benzyl.
2. synthetic method according to claim 1 is characterized in that, the fatty alkyl of described 1～10 carbon is methyl, ethyl or propyl group, and described substituted-phenyl is a p-methylphenyl, and described substituted benzyl is to methoxy-benzyl.
3. synthetic method according to claim 1 is characterized in that, the reaction mol ratio of the compound shown in compound shown in the described formula (I) and the formula (II) is 1: 1～1: 5.
4. synthetic method according to claim 1 is characterized in that, described alkali is selected from one or more in sodium alkoxide, potassium alcoholate, butyllithium, isobutyl-lithium, tert-butyl lithium, sodium hydroxide, potassium hydroxide, lithium hydroxide, cesium hydroxide and the salt of wormwood.
5. synthetic method according to claim 1 is characterized in that, the concentration of described alkali is 0.1～10M.
6. synthetic method according to claim 1, it is characterized in that, described organic solvent is selected from tetrahydrofuran (THF), ether, methylene dichloride, 1, one or more in alcohol, toluene, ethyl acetate, dimethyl formamide, methyl-sulphoxide and the dimethylbenzene of 2-ethylene dichloride, acetonitrile, 1～4 carbon.
7. synthetic method according to claim 1 is characterized in that, temperature of reaction is 0～80 ℃.
8. synthetic method according to claim 1 is characterized in that, the reaction times is for till detecting reaction raw materials and no longer reducing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810202634 CN101735196B (en) | 2008-11-12 | 2008-11-12 | Method for synthesizing Imatinib |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200810202634 CN101735196B (en) | 2008-11-12 | 2008-11-12 | Method for synthesizing Imatinib |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101735196A true CN101735196A (en) | 2010-06-16 |
| CN101735196B CN101735196B (en) | 2013-03-20 |
Family
ID=42459274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200810202634 Active CN101735196B (en) | 2008-11-12 | 2008-11-12 | Method for synthesizing Imatinib |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101735196B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130918A1 (en) * | 2010-04-23 | 2011-10-27 | 上海百灵医药科技有限公司 | Process for synthesizing imatinib |
| WO2012131711A1 (en) * | 2011-03-31 | 2012-10-04 | Ind-Swift Laboratories Limited | Improved process for preparation of imatinib and its mesylate salt |
| CN105859682A (en) * | 2015-01-18 | 2016-08-17 | 杨俊� | Synthetic method of imatinib mesylate |
| CN112920163A (en) * | 2021-01-26 | 2021-06-08 | 华中科技大学同济医学院附属协和医院 | Hapten, antigen and antibody of imatinib and N-demethyl imatinib and application thereof |
| CN112946282A (en) * | 2021-01-26 | 2021-06-11 | 北京丹大生物技术有限公司 | Detection reagent and detection kit for detecting imatinib and/or N-demethylimatinib |
-
2008
- 2008-11-12 CN CN 200810202634 patent/CN101735196B/en active Active
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011130918A1 (en) * | 2010-04-23 | 2011-10-27 | 上海百灵医药科技有限公司 | Process for synthesizing imatinib |
| WO2012131711A1 (en) * | 2011-03-31 | 2012-10-04 | Ind-Swift Laboratories Limited | Improved process for preparation of imatinib and its mesylate salt |
| US8912325B2 (en) | 2011-03-31 | 2014-12-16 | Ind-Swift Laboratories Limited | Process for preparation of imatinib and its mesylate salt |
| CN105859682A (en) * | 2015-01-18 | 2016-08-17 | 杨俊� | Synthetic method of imatinib mesylate |
| CN112920163A (en) * | 2021-01-26 | 2021-06-08 | 华中科技大学同济医学院附属协和医院 | Hapten, antigen and antibody of imatinib and N-demethyl imatinib and application thereof |
| CN112946282A (en) * | 2021-01-26 | 2021-06-11 | 北京丹大生物技术有限公司 | Detection reagent and detection kit for detecting imatinib and/or N-demethylimatinib |
| CN112946282B (en) * | 2021-01-26 | 2022-08-09 | 北京丹大生物技术有限公司 | Detection reagent and detection kit for detecting imatinib and/or N-demethylimatinib |
| CN112920163B (en) * | 2021-01-26 | 2023-09-26 | 华中科技大学同济医学院附属协和医院 | Hapten, antigen and antibody of imatinib and N-demethyl imatinib and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101735196B (en) | 2013-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101735196B (en) | Method for synthesizing Imatinib | |
| CN100451015C (en) | Preparing method of imatinib | |
| CN101497601B (en) | Process for synthesizing imatinib | |
| CN102020633B (en) | Method for preparing 1-(3,5- dichloropyridine-2-yl)-pyrazolecarboxamide compounds | |
| JP6096891B2 (en) | N-aryl unsaturated condensed ring tertiary amine compound, preparation method thereof and antitumor use | |
| US9856215B2 (en) | Preparation method of Nintedanib | |
| CN103772278A (en) | Important tetrahydroisoquinoline derivative midbody and synthesis method thereof | |
| CN102079725A (en) | Method for preparing 2-chloropyrimidine | |
| IE54620B1 (en) | 2-(4-((4,4-dialkyl-2,6-piperidinedion-1-yl)butyl)-1-piperazinyl) pyridines | |
| CN101531654B (en) | Preparation method for Rupatadine | |
| CN103373989A (en) | Preparation method of intermediate of pazopanib hydrochloride | |
| CN105037236A (en) | Ribociclib intermediate and preparation method thereof | |
| CN101704796B (en) | Preparation method of 3-morpholone | |
| CN101654416B (en) | N-[3-nitro-4-methyl-phenyl]-4-aldehyde group-benzamide and preparation method thereof as well as preparation method of derivatives thereof | |
| EP2509973A1 (en) | Process for the preparation of imatinib and salts thereof | |
| CN102295607A (en) | Inverse phase transfer catalysis preparation method for urapidil | |
| CN104744311B (en) | Synthesis method of bifenazate | |
| CN101195626A (en) | Method for synthesizing pyrazole [3,4-d] pyrimidine-4(5H)-ketone compounds | |
| CN103113375B (en) | Pyrazole simultaneously [3,4 d] pyrimidines and preparation method thereof | |
| CN111039921A (en) | Synthesis process of imatinib and imatinib mesylate | |
| CN110256342A (en) | A kind of synthetic method of 2- cyano-quinoline derivatives | |
| CN105315169A (en) | Preparation method for cardiovascular disease treatment drug | |
| CN101857549A (en) | Synthetic method of (1S)-4,5-Dimethoxy-1-(aminomethyl)benzocyclobutane | |
| CN102993088A (en) | 4-hydroxy-2-pyridone preparation method | |
| CN107652271A (en) | A kind of Topiroxostat crystal formation I preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160707 Address after: Mingxi County of Sanming City province Fujian 365200 Xuefeng New Town Road No. 98 Patentee after: Fujian South Pharmaceutical Co., Ltd. Address before: 200444, No. 868, Chen Cheng Road, No. 2, Shanghai, Baoshan District Patentee before: Parling Shanghai Pharm-technology Co., Ltd. Patentee before: Fujian South Pharmaceutical Co., Ltd. |